The long-term outlook for the US Liver Biopsy Market remains strong, driven by rising chronic liver disease prevalence, increasing transplant volumes, and continuing demand for precise histological diagnostics. Forecasts indicate sustained growth as new therapeutic developments (for NASH, liver cancer, fibrosis reversal, etc.) rely on biopsy-confirmed endpoints. This anticipated trajectory is...